A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry

Jennifer G. Whisenant; Javier Baena; Alessio Cortellini; Li-Ching Huang; Giuseppe Lo Russo; Luca Porcu; Selina K. Wong; Christine M. Bestvina; Matthew D. Hellmann; Elisa Roca; Hira Rizvi; Isabelle Monnet; Amel Boudjemaa; Jacobo Rogado; Giulia Pasello; Natasha B. Leighl; Oscar Arrieta; Avinash Aujayeb; Ullas Batra; Ahmed Y. Azzam; Mojca Unk; Mohammed A. Azab; Ardak N. Zhumagaliyeva; Carlos Gomez-Martin; Juan B. Blaquier; Erica Geraedts; Giannis Mountzios; Gloria Serrano-Montero; Niels Reinmuth; Linda Coate; Melina Marmarelis; Carolyn J. Presley; Fred R. Hirsch; Pilar Garrido; Hina Khan; Alice Baggi; Celine Mascaux; Balazs Halmos; Giovanni L. Ceresoli; Mary J. Fidler; Vieri Scotti; Anne-Cécile Métivier; Lionel Falchero; Enriqueta Felip; Carlo Genova; Julien Mazieres; Umit Tapan; Julie Brahmer; Emilio Bria; Sonam Puri; Sanjay Popat; Karen L. Reckamp; Floriana Morgillo; Ernest Nadal; Francesca Mazzoni; Francesco Agustoni; Jair Bar; Federica Grosso; Virginie Avrillon; Jyoti D. Patel; Fabio Gomes; Ehab Ibrahim; Annalisa Trama; Anna C. Bettini; Fabrice Barlesi; Anne-Marie Dingemans; Heather Wakelee; Solange Peters; Leora Horn; Marina Chiara Garassino; Valter Torri; TERAVOLT study group

doi:10.1016/j.jtho.2021.12.015

Back

A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry

Journal article

Open access

Peer reviewed

A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry

Jennifer G. Whisenant, Javier Baena, Alessio Cortellini, Li-Ching Huang, Giuseppe Lo Russo, Luca Porcu, Selina K. Wong, Christine M. Bestvina, Matthew D. Hellmann, Elisa Roca, …

Journal of thoracic oncology, Vol.17(5), pp.661-674

01/05/2022

DOI: https://doi.org/10.1016/j.jtho.2021.12.015

PMID: 35121086

Abstract

Cancer

COVID-19

NSCLC

Registry

TERAVOLT

Thoracic

Patients with thoracic malignancies are at increased risk for mortality from coronavirus disease 2019 (COVID-19), and a large number of intertwined prognostic variables have been identified so far. Capitalizing data from the Thoracic Cancers International COVID-19 Collaboration (TERAVOLT) registry, a global study created with the aim of describing the impact of COVID-19 in patients with thoracic malignancies, we used a clustering approach, a fast-backward step-down selection procedure, and a tree-based model to screen and optimize a broad panel of demographics and clinical COVID-19 and cancer characteristics. As of April 15, 2021, a total of 1491 consecutive eligible patients from 18 countries were included in the analysis. With a mean observation period of 42 days, 361 events were reported with an all-cause case fatality rate of 24.2%. The clustering procedure screened 73 covariates in 13 clusters. A further multivariable logistic regression for the association between clusters and death was performed, resulting in five clusters significantly associated with the outcome. The fast-backward step-down selection procedure then identified the following seven major determinants of death: Eastern Cooperative Oncology Group—performance status (ECOG-PS) (OR = 2.47, 1.87–3.26), neutrophil count (OR = 2.46, 1.76–3.44), serum procalcitonin (OR = 2.37, 1.64–3.43), development of pneumonia (OR = 1.95, 1.48–2.58), C-reactive protein (OR = 1.90, 1.43–2.51), tumor stage at COVID-19 diagnosis (OR = 1.97, 1.46–2.66), and age (OR = 1.71, 1.29–2.26). The receiver operating characteristic analysis for death of the selected model confirmed its diagnostic ability (area under the receiver operating curve = 0.78, 95% confidence interval: 0.75–0.81). The nomogram was able to classify the COVID-19 mortality in an interval ranging from 8% to 90%, and the tree-based model recognized ECOG-PS, neutrophil count, and c-reactive protein as the major determinants of prognosis. From 73 variables analyzed, seven major determinants of death have been identified. Poor ECOG-PS was found to have the strongest association with poor outcome from COVID-19. With our analysis, we provide clinicians with a definitive prognostication system to help determine the risk of mortality for patients with thoracic malignancies and COVID-19.

Files and links (1)

url

https://doi.org/10.1016/j.jtho.2021.12.015View

Published (Version of record) Open

Metrics

1 Record Views

See more details

Details

Title: A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry
Creators - without role: Jennifer G. Whisenant - Vanderbilt University Medical Center
Javier Baena - Hospital Universitario 12 De Octubre
Alessio Cortellini - Imperial College London
Li-Ching Huang - Vanderbilt University Medical Center
Giuseppe Lo Russo - Thoracic Oncology Unit, Medical Oncology Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori, Milan, Italy
Luca Porcu - Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy
Selina K. Wong - Vanderbilt University Medical Center
Christine M. Bestvina - University of Chicago
Matthew D. Hellmann - Memorial Sloan Kettering Cancer Center
Elisa Roca - Thoracic Oncology—Lung Unit, Ospedale Pederzoli, Peschiera d/G, Verona, Italy
Hira Rizvi - Memorial Sloan Kettering Cancer Center
Isabelle Monnet - Hôpital Intercommunal de Créteil
Amel Boudjemaa - Hôpital Intercommunal de Créteil
Jacobo Rogado - Hospital Universitario Infanta Leonor
Giulia Pasello - University of Padua
Natasha B. Leighl - Division of Medical Oncology/Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
Oscar Arrieta - Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), México City, México
Avinash Aujayeb - Northumbria Healthcare NHS Foundation Trust
Ullas Batra - Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Center, New Delhi, India
Ahmed Y. Azzam - October 6 University
Mojca Unk - Institute of Oncology Ljubljana
Mohammed A. Azab - Cairo University
Ardak N. Zhumagaliyeva - Semey Medical University
Carlos Gomez-Martin - Hospital Universitario 12 De Octubre
Juan B. Blaquier - Thoracic Oncology Section, Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Buenos Aires, Argentina
Erica Geraedts - Groene Hart Ziekenhuis
Giannis Mountzios - Henry Dunant Hospital
Gloria Serrano-Montero - Hospital Universitario Infanta Leonor
Niels Reinmuth - Asklepios Kliniken GmbH, Asklepios Fachkliniken Muenchen, Gauting, Germany
Linda Coate - Cancer Trials Ireland
Melina Marmarelis - University of Pennsylvania
Carolyn J. Presley - The Ohio State University
Fred R. Hirsch - Center for Thoracic Oncology, Tisch Cancer Institute and Icahn School of Medicine Mount Sinai, New York, New York
Pilar Garrido - Hospital Universitario Ramón y Cajal
Hina Khan - Brown University
Alice Baggi - University of Brescia
Celine Mascaux - Hôpitaux Universitaires de Strasbourg
Balazs Halmos - Albert Einstein College of Medicine
Giovanni L. Ceresoli - Humanitas Gavazzeni
Mary J. Fidler - Rush University Medical Center
Vieri Scotti - Department of Oncology, Radiation Therapy Unit, Careggi University Hospital, Florence, Italy
Anne-Cécile Métivier - Hôpital Foch
Lionel Falchero - Hôpital Nord
Enriqueta Felip - Hebron University
Carlo Genova - Ospedale Policlinico San Martino
Julien Mazieres - Toulouse University Hospital, Institut Universitaire du Cancer, Université Paul Sabatier, Toulouse, France
Umit Tapan - Boston University School of Medicine
Julie Brahmer - Sidney Kimmel Cancer Center
Emilio Bria - Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
Sonam Puri - University of Utah
Sanjay Popat - Lung Unit, Royal Marsden National Health Service Foundation Trust, London, United Kingdom
Karen L. Reckamp - Cedars-Sinai Medical Center
Floriana Morgillo - Studi
Ernest Nadal - Thoracic Oncology Unit, Department of Medical Oncology, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain
Francesca Mazzoni - Medical Oncology, Careggi University Hospital, Florence, Italy
Francesco Agustoni - Medical Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy
Jair Bar - Tel Aviv University
Federica Grosso - Mesothelioma and Rare Cancer Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
Virginie Avrillon - Centre Léon Bérard
Jyoti D. Patel - Division of Hematology and Oncology, Northwestern University, Chicago, Illinois
Fabio Gomes - The Christie NHS Foundation Trust
Ehab Ibrahim - The Clatterbridge Cancer Center NHS Foundation Trust, Birkenhead, United Kingdom
Annalisa Trama - Fondazione IRCCS Istituto Nazionale dei Tumori
Anna C. Bettini - Medical Oncology Department, ASST Papa Giovanni XXIII, Bergamo, Italy
Fabrice Barlesi - Aix-Marseille University
Anne-Marie Dingemans - Erasmus MC
Heather Wakelee - Stanford University
Solange Peters - University Hospital of Lausanne
Leora Horn - Vanderbilt University Medical Center
Marina Chiara Garassino - University of Chicago
Valter Torri - Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy
TERAVOLT study group
Publication Details: Journal of thoracic oncology, Vol.17(5), pp.661-674
Publisher: Elsevier Inc
Identifiers: 9913269108331
Academic Unit: Alfaisal University
Language: English
Resource Type: Journal article